Featured | 2020 ESMO Oncology Research and Development Trends

Recently, the European Society of Medical Oncology (ESMO) 2020 web conference is under way, the major pharmaceutical companies are sharing their latest cancer treatment progress.
Pharmaceuticals first selected important research and development developments and shared them with you: The CheckMate-214 study of BMS BMS showed that more than half of patients with advanced kidney cancer (RCC) who received a combined treatment of Opdivo (nivolumab) and Yerevoy (ipilimumab) survived four years later.
this is the longest follow-up study of immunotherapy-based combination therapy in patients with untreated advanced kidney cancer.
BMS said the benefits of continuous survival were observed in major patient groups, patient groups with moderate and adverse risk prognosis factors, and intentional therapy (ITT, i.e. all random) patient groups.
total survival (OS) was 48.1 months for patients with medium and low risk who received combined therapy.
, Pfizer's Sunitinib has 26.6 months of OS.
BMS noted that the four-year OS rate for double immunotherapy was 50 percent, compared with 35.8 percent for the Schoenicinib group.
, Opdivo and Yervoy are generally more efficient than Pfizer's drugs, with a difference of 65 percent to 50 percent.
NOXXON Pharma NOXXON Pharma published the results of phase I/II studies in patients with a combined treatment of CXCL12 inhibitors NOX-A12 and pembrolizumab in patients with microsatellitre stability, metastatic colorectal cancer, or pancreatic cancer.
said some patients treated with advanced cancer had increased immune response and long survival times, while final data confirmed the overall safety of combined therapies, supported plans for further research, and established standards for care options in early treatment routes.
the study received an average of six-line treatment, and the results showed that 25 percent of the patients in the study were stable.
NOX-A12 can penetrate cancerous tissue in patients with pancreatic and colorectal cancer, where it targets CXCL12.
when baseline biopsies were compared with samples treated with single-use NOX-A12, it was found that NOX-A12 single-drug therapy induced patients to develop Th1-like immune responses.
and the combined treatment of NOX-A12 with pembrolizumab can stabilize 25 percent of patients;
39 per cent at six months and 20 per cent at 12 months.
Bayer Bayer has released new clinical data on Vitrakvi (larotrectinib), further demonstrating the drug's consistency, long-term efficacy and safety in adult and child primary myoglobulin-infested kinase (TRK) fusion cancer patients.
and a new tumor type-specific subtype analysis conducted in patients with lung and thyroid cancer further highlighted Vitrakvi's long-lasting response to these cancers, with no new safety signals reported.
Vitrakvi had a total lasting effect of 78%, of which 19% were fully remission (CR), 59% were partially remission and 13% were stable.
ORR was 71% in 14 CNS metastasis patients.
, after 13.8 months of medium follow-up, the patient's medium progressity-free lifetime (PFS) was 36.8 months.
15.3 months of follow-up, the medium OS rate was not reached, the 12-month projected mid-OS rate was 90 percent, and the 24-month projected OS rate was 83 percent.
Center Therapeutics Checkpoint Therapeutics announced the positive results of its mid-term analysis of the anti-PD-L1 antibody cosibelimab trial for patients with advanced cancer Phase 1.
the company noted that cosibelimab's objective mitigation rate (ORR) was 51.4 per cent and its CR rate was 13.5 per cent, almost double the CR rate observed in the previous analysis.
Checkpoint President and CEO James F. Oliviero said in a statement: "The latest interim results demonstrate cosibelimab's potential best-in-class efficacy and safety, with low observation rates for serious adverse events."
importantly, orR and CR rates were observed higher in key patient queues than in patients with metastatic skin squamous cell carcinoma (mCSCC) with two existing regulatoryly approved anti-PD-1 drugs.
think this is due to cosibelimab's dual mechanism of action, which activates both T-cells and natural killer cells to enhance their efficacy.
" Immunicum Immunicum announced in a poster presentation for ESMO preclinical support data used by iixadencel, an off-the-go cellular immunosumagide, in combination with cancer treatments and immunotherapy, including anti-VEGF, anti-PD1, and anti-CTLA4.
Early results from preclinical studies conducted in mice showed stronger anti-tumor responses in animals treated with a combination of ilixadencel and anti-CTLA4 drugs than those treated with anti-PD1 and CTLA4 combinations of checkpoint inhibitors.
in additional experiments completed, Immunicum observed that when iixadencel was used in association with anti-vascular endostrophic growth factor (VEGF), anti-CTLA4, or in association with anti-CTLA4 and anti-PD1, it was completely reactive in the colon cancer tumor model (CT26) in mice.
source: A Look at ESMO as Companies Share Oncology Updates.